CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Inclusion Criteria: * Fulfill at least 4 diagnostic criteria for SLE defined by American College of Rheumatology * Positive antinuclear antibodies (ANA) and/or anti-double stranded DNA (anti-dsDNA) * Active SLE disease as defined by SELENA-SLEDAI score ≥10 despite on-going stable corticosteroid therapy * Subjects with stable nephritis may be enrolled * 18 years of age or older Exclusion Criteria: * Severe active vasculitis, active central nervous system lupus, uncontrolled hypertension or poorly controlled diabetes * Malignancy within past 5 years * Known to be positive for HIV and/or positive at the screening visit for hepatitis B, or hepatitis C * Liver disease * Anemia, neutropenia, or thrombocytopenia * Active infection requiring hospitalization or treatment with parenteral antibiotics within the past 60 days or history of repeated herpetic viral infections * History of active tuberculosis or a history of tuberculosis infection * Pregnant or nursing